This filing is routine and does not provide new trading information. Monitor subsequent filings for operational progress of the post-merger entity, particularly pipeline updates or capital raises that could affect the micro-cap stock.
Price Chart
Executive Summary
Decoy Therapeutics filed Amendment No. 1 to its 2025 10-K to include Part III items (directors, executive compensation, security ownership, related transactions, and auditor fees) that were omitted from the original filing, as the company will not file a proxy statement within 120 days. The amendment is purely administrative and contains no financial restatements or new business developments.
Key Facts
- Amendment adds Items 10-14 (corporate governance, compensation, ownership, related party transactions, auditor fees) to the 2025 10-K.
- No financial statements or restatements are included; the original 10-K financials remain unchanged.
- Merger with Legacy Decoy closed on November 12, 2025; name changed to Decoy Therapeutics Inc.
- Audit fees increased to $908,179 in 2025 from $255,038 in 2024, reflecting merger-related work.
- CVI Investments, Inc. holds 9.9% of outstanding common stock as of April 30, 2026.
Financial Impact
No material financial impact; the amendment is procedural.
Risk Factors
- Micro-cap biotech with $3M market cap; high volatility and liquidity risk.
- No revenue-generating products; reliance on future financing.
- Audit fee increase may indicate complexity, but no adverse findings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-195909 |
| Document: dcoy-ex31_4.htm | 0001193125-26-195909 |
| Document: dcoy-ex31_3.htm | 0001193125-26-195909 |
| Document: 0001193125-26-195909-index-headers.html | 0001193125-26-195909 |
| Document: 0001193125-26-195909-index.html | 0001193125-26-195909 |
| Document: 0001193125-26-195909.txt | 0001193125-26-195909 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | EFFECT | $1.17 $0.9100 | ▼ −22.22% | ▼ −22.08% | $1.01 (−13.68%) |
Oct 7, 2026 19d ago | S-1 | $1.52 $1.23 | ▲ +19.08% | ▲ +18.80% | $1.01 (+33.55%) |
Sep 23, 2026 4w ago | 8-K | $3.11 $1.86 | ▲ +40.35% | ▲ +39.94% | $1.01 (+67.52%) |
Aug 4, 2026 11w ago | DEFA14A | $4.19 $3.60 | ▼ −14.08% | ▼ −14.43% | $1.01 (−75.89%) |
Jul 20, 2026 14w ago | EFFECT | $5.31 $3.74 | ▼ −29.50% | ▼ −29.10% | $1.01 (−80.96%) |
Jun 29, 2026 17w ago | 8-K | $9.59 $7.25 | ▲ +24.40% | ▲ +25.79% | $1.01 (+89.47%) |
Jun 25, 2026 17w ago | EFFECT | $5.92 $7.62 | ▲ +28.76% | ▲ +27.20% | $1.01 (−82.93%) |
Jun 4, 2026 20w ago | DEFA14A | $6.71 $5.90 | ▼ −12.07% | ▼ −9.52% | $1.01 (−84.95%) |
Apr 30, 2026 25w ago | 10-K/A | $6.05 $6.01 | ▼ −0.66% | ▼ −2.39% | $1.01 (−83.31%) |
Apr 2, 2026 29w ago | 8-K | $5.80 $5.84 | ▲ +0.69% | ▼ −2.93% | $1.01 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers